Factors contributing to carboplatin blockade and interruption in its route of administration in paclitaxel-carboplatin therapy

被引:0
|
作者
Inoue, Motoki [1 ]
Nakadate, Kazuhiko [1 ]
Oosaki, Mami [2 ]
Shirota, Mikio [2 ]
Yasu, Takeo [1 ,2 ,3 ,4 ]
机构
[1] Meiji Pharmaceut Univ, Tokyo, Japan
[2] Tokyo Metropolitan Bokutoh Hosp, Dept Pharm, Tokyo, Japan
[3] Meiji Pharmaceut Univ, Bokutoh Hosp, Joint Res Ctr, Tokyo, Japan
[4] Meiji Pharmaceut Univ, Pharmaceut Educ & Res Ctr, Dept Med Therapy Res, 2 522 1 Noshio, Kiyose, Tokyo 2048588, Japan
来源
DRUG DISCOVERIES AND THERAPEUTICS | 2023年 / 17卷 / 03期
关键词
adsorption; catheters; scanning electron microscopy; syringe pushing force;
D O I
10.5582/ddt.2022.01121
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The interruption of anticancer infusion processes in patients undergoing chemotherapy may affect their quality of life and the efficacy and safety of the therapy. We experienced several interruptions of carboplatin infusion in multiple patients receiving paclitaxel-carboplatin combination therapy. Therefore, we investigated the causes of these interruptions. The filter and catheter surfaces were evaluated by scanning electron microscopy. Moreover, using a texture analyzer, the mechanical strengths of catheter-attached syringes were compared pre- and post-administration. We observed that the syringe pushing force requirement was higher following dripping failure. However, precipitates were not evident on the filter surfaces, regardless of the dripping failure route. In this case, some of the drug adhered to the catheters' surfaces and interrupted the carboplatin titration. Consequently, in patients receiving combination therapy with paclitaxel and carboplatin, and experiencing interruptions in carboplatin infusion, attention should be paid to the catheter.
引用
收藏
页码:214 / 216
页数:3
相关论文
共 50 条
  • [31] Abandon ifosfamide-based regimen and use paclitaxel-carboplatin regimen for the treatment of uterine carcinosarcoma
    Yang, Szu-Ting
    Wang, Peng-Hui
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2022, 85 (05) : 649 - 650
  • [32] Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer - Accumulating evidence for synergy, efficacy, and safety
    Pentheroudakis, G
    Razis, E
    Athanassiadis, A
    Pavlidis, N
    Fountzilas, G
    MEDICAL ONCOLOGY, 2006, 23 (02) : 147 - 160
  • [33] Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck
    Pivot, X
    Cals, L
    Cupissol, D
    Guardiola, E
    Tchiknavorian, X
    Guerrier, P
    Merad, L
    Wendling, JL
    Barnouin, L
    Savary, J
    Thyss, A
    Schneider, M
    ONCOLOGY, 2001, 60 (01) : 66 - 71
  • [34] Sequentially insert of carboplatin followed by Paclitaxel in the first-line therapy for ovarian cancer carboplatin followed by Paclitaxel in the therapy for ovarian cancer
    Sehouli, J.
    Mustea, A.
    Pfisterer, J.
    Camara, O.
    Lichtenegger, W.
    Oskay-Oezcelik, G.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S70 - S70
  • [35] Phase I/II study everolimus in combination with paclitaxel-carboplatin in patients with advanced adenocarcinoma of the stomach
    Loong, H. H.
    Mo, F.
    Li, L.
    Lee, C.
    Lam, K-C.
    Koh, J.
    Chiu, P.
    Teoh, A.
    Chan, A. T. C.
    Ng, E.
    Yeo, W.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer
    Isonishi, Seiji
    Suzuki, Masaaki
    Nagano, Hiroaki
    Takagi, Koichiro
    Shimauchi, Masahito
    Kawabata, Masakiyo
    Ochiai, Kazuhiko
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2013, 24 (02) : 154 - 159
  • [37] Weekly paclitaxel-carboplatin (WPCB) as frontline chemotherapy in metastatic endometrial cancer: A phase II study
    Lanzetta, G.
    Rozzi, A.
    Nardoni, C.
    Corona, M.
    Fanfani, F.
    Scambia, G.
    ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
  • [38] Phase II study comparing paclitaxel-carboplatin alone with paclitaxel-carboplatin plus bevacizumab in previously untreated Japanese patients with advanced-stage non-squamous non-small cell lung cancer (NSCLC)
    Asahina, Hajime
    Kunitoh, Hideo
    Ichinose, Yukito
    Horai, Takeshi
    Nishiwaki, Yutaka
    Hida, Toyoaki
    Yamamoto, Nobuyuki
    Kawahara, Masaaki
    Saijo, Nagahiro
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S285 - S285
  • [39] Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma
    Barlin, Joyce N.
    Mahar, Barb
    Ata, Ashar
    Cormier, Beatrice
    Michelin, David
    Salani, Ritu
    Backes, Floor
    Levinson, Kimberly
    Cantrell, Leigh Anne
    Weinberg, Lori
    Wagreich, Allison
    Savage, Duncan
    Gasson, Christian
    Denniston, Kyle
    Martin, Jovana
    McElrath, Timothy
    Timmins, Patrick F.
    GYNECOLOGIC ONCOLOGY, 2024, 180 : 63 - 69
  • [40] Combination therapy of docetaxel, carboplatin or paclitaxel, carboplatin for patients with metastatidrecurrent carcinoma of the head and neck (SCCHN).
    Bickmann, A.
    Holzgraefe, M.
    Wolf, M.
    Schroeder, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 299S - 299S